EP2975054A4 - Anti-staphylococcus antibody, method for manufacturing same, and usage of same - Google Patents

Anti-staphylococcus antibody, method for manufacturing same, and usage of same

Info

Publication number
EP2975054A4
EP2975054A4 EP14765434.7A EP14765434A EP2975054A4 EP 2975054 A4 EP2975054 A4 EP 2975054A4 EP 14765434 A EP14765434 A EP 14765434A EP 2975054 A4 EP2975054 A4 EP 2975054A4
Authority
EP
European Patent Office
Prior art keywords
same
usage
manufacturing
staphylococcus antibody
staphylococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14765434.7A
Other languages
German (de)
French (fr)
Other versions
EP2975054A1 (en
Inventor
Hiroyoshi OHSAWA
Jumpei ENAMI
Keiichi Hiramatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenyaku Kogyo KK
Juntendo Educational Foundation
Original Assignee
Zenyaku Kogyo KK
Juntendo Educational Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo KK, Juntendo Educational Foundation filed Critical Zenyaku Kogyo KK
Publication of EP2975054A1 publication Critical patent/EP2975054A1/en
Publication of EP2975054A4 publication Critical patent/EP2975054A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP14765434.7A 2013-03-12 2014-03-11 Anti-staphylococcus antibody, method for manufacturing same, and usage of same Withdrawn EP2975054A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013049268 2013-03-12
PCT/JP2014/056324 WO2014142117A1 (en) 2013-03-12 2014-03-11 Anti-staphylococcus antibody, method for manufacturing same, and usage of same

Publications (2)

Publication Number Publication Date
EP2975054A1 EP2975054A1 (en) 2016-01-20
EP2975054A4 true EP2975054A4 (en) 2016-11-23

Family

ID=51536771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14765434.7A Withdrawn EP2975054A4 (en) 2013-03-12 2014-03-11 Anti-staphylococcus antibody, method for manufacturing same, and usage of same

Country Status (4)

Country Link
US (1) US9809645B2 (en)
EP (1) EP2975054A4 (en)
JP (1) JP6371758B2 (en)
WO (1) WO2014142117A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703774T3 (en) 2010-06-18 2019-03-12 Xbiotech Inc Treatment for arthritis
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
CA2913011A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
CA3012046C (en) 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059259A2 (en) * 2001-12-21 2003-07-24 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
WO2003063772A2 (en) * 2001-12-21 2003-08-07 Biosynexus Incorporated Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2011008092A2 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
US20110236399A1 (en) * 2010-03-29 2011-09-29 Biosynexus Incorporated Compositions and methods for prophylactic and therapeutic treatment of infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CN101001874B (en) * 2004-04-21 2012-12-19 布赖汉姆妇女医院 Poly-n-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059259A2 (en) * 2001-12-21 2003-07-24 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
WO2003063772A2 (en) * 2001-12-21 2003-08-07 Biosynexus Incorporated Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2011008092A2 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
US20110236399A1 (en) * 2010-03-29 2011-09-29 Biosynexus Incorporated Compositions and methods for prophylactic and therapeutic treatment of infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FATTOM A I ET AL: "Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 66, no. 10, 1 October 1998 (1998-10-01), pages 4588 - 4592, XP002153789, ISSN: 0019-9567 *
HIROYOSHI OHSAWA ET AL: "Successful selection of an infection-protective anti- Staphylococcus aureus monoclonal antibody and its protective activity in murine infection models", MICROBIOLOGY AND IMMUNOLOGY, vol. 59, no. 4, 1 April 2015 (2015-04-01), JP, pages 183 - 192, XP055311124, ISSN: 0385-5600, DOI: 10.1111/1348-0421.12242 *
SCHAFFER A C ET AL: "Staphylococcal Vaccines and Immunotherapies", INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, SAUNDERS CO., LONDON, GB, vol. 23, no. 1, 1 March 2009 (2009-03-01), pages 153 - 171, XP009144767, ISSN: 0891-5520, [retrieved on 20090109], DOI: 10.1016/J.IDC.2008.10.005 *
See also references of WO2014142117A1 *

Also Published As

Publication number Publication date
JP6371758B2 (en) 2018-08-08
WO2014142117A1 (en) 2014-09-18
US9809645B2 (en) 2017-11-07
JPWO2014142117A1 (en) 2017-02-16
US20160024190A1 (en) 2016-01-28
EP2975054A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
IL291446A (en) Anti-trop2 antibodies and methods for producing same
EP2970505A4 (en) Bispecific antibodies and uses thereof
HK1223953A1 (en) Humanized anti-tau(ps422) antibodies and methods of use -tau(ps422)
EP2949457A4 (en) Shoes and method for manufacturing same
EP2949783A4 (en) Sliding member and method for producing same
EP2952490A4 (en) Optical-fiber preform and method for manufacturing optical-fiber preform
HK1223533A1 (en) Ultrasonic instrument and method for manufacturing same
EP2979542A4 (en) Method for manufacturing excreta-processing material and excreta-processing material
SG11201508847WA (en) Electroformed component and method for manufacturing same
EP2975054A4 (en) Anti-staphylococcus antibody, method for manufacturing same, and usage of same
EP2966699A4 (en) Thermoelectric converter and method for manufacturing same
LT3043814T (en) Antigen and method for production thereof
GB201300706D0 (en) Antibody
EP2950360A4 (en) Method for manufacturing thermoelectric converter
HK1221127A1 (en) Cosmetic eyelid-reshaping tape and method for manufacturing same
EP2985541A4 (en) Duct and method for manufacturing same
EP2975125A4 (en) Microvesicle, and manufacturing method for same
EP2953171A4 (en) Semiconductor optical device, and method for manufacturing semiconductor optical device
EP2978011A4 (en) Method for manufacturing complex, and composition
EP2952895A4 (en) Method of producing labeled antibody
EP2977923A4 (en) Program for designing compound, device for designing compound, and method for designing compound
EP3046122A4 (en) Reactor device and method for manufacturing reactor device
EP3020416A4 (en) Ultrafast-disintegrating tablet and method for manufacturing same
EP2980572A4 (en) Biosensor and manufacturing method therefor
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161026

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20161020BHEP

Ipc: A61P 31/04 20060101ALI20161020BHEP

Ipc: C12P 21/08 20060101ALI20161020BHEP

Ipc: C12N 1/19 20060101ALI20161020BHEP

Ipc: C12N 1/21 20060101ALI20161020BHEP

Ipc: C12N 1/15 20060101ALI20161020BHEP

Ipc: C12N 15/09 20060101ALI20161020BHEP

Ipc: C12N 15/02 20060101ALI20161020BHEP

Ipc: A61K 39/395 20060101ALI20161020BHEP

Ipc: C07K 16/12 20060101AFI20161020BHEP

Ipc: C12N 5/10 20060101ALI20161020BHEP

17Q First examination report despatched

Effective date: 20171024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190227